Bluejay’s SYMON II study for its rapid IL-6 sepsis risk platform is proceeding on schedule, with site activities and patient enrollment aligning with internal timelines. Data from this trial will underpin the company’s FDA regulatory submission and will be disclosed when primary endpoints are analyzed.

The company has advanced its manufacturing scale-up strategy, executing process validation and securing critical raw materials, antibody supply, and cartridge manufacturing preparations. External manufacturing coordination and supply-chain initiatives are on track to support both clinical and future commercial production.

As of December 31, 2025, Bluejay held $5.2 million in cash and $6.0 million in stockholders’ equity, with approximately 972,000 common shares outstanding following prefunded warrant conversions. The company reported a $6.8 million net loss for fiscal 2025 and previously raised $3.8 million via warrant inducement and $4.5 million in a PIPE financing.

Bluejay’s 2026 roadmap focuses on completing SYMON II and progressing toward FDA submission, scaling manufacturing operations, strengthening supply-chain robustness, enhancing Symphony platform capabilities, engaging investors and partners, and securing at least $20 million in additional capital through fiscal 2027.